Reporte zur Charge 1FF8841

Symptomtext

Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter (Consumer or other non HCP). The reporter is the patient. A female patient (not pregnant) received BNT162b2 (Pfizer-BioNTech COVID-19), on 20Mar2021 at 11:00 as dose 1, single (Lot number: ER2613) at the age of 36 years, in right arm, on 14Apr2021 at 12:30 as dose 2, single (Lot number: EW0614) at the age of 36 years, in left arm and on 21Oct2021 at 15:00 as dose 3 (booster), single (Lot number: 1FF8841) at the age of 37 years, in right arm for covid-19 immunisation. The patient's relevant medical history included: "Depression" (unspecified if ongoing); "high cholesterol" (unspecified if ongoing); "severe seasonal allergies" (unspecified if ongoing), notes: severe seasonal allergies; "herpies" (unspecified if ongoing), notes: herpies; "GERD" (unspecified if ongoing); "known allergies: Sulfa based meds" (unspecified if ongoing), notes: known allergies: Sulfa based meds. Concomitant medication(s) included: ROSUVASTATIN CALCIUM, start date: 01Apr2021, stop date: 27Jun2022; ESTRADIOL, start date: 01Sep2021; OMEPRAZOLE, start date: 01Mar2010; VALACYCLOVIR HCL, start date: 01Jul2016; SERTRALINE HCL, start date: 01Oct2016; LORATADINE, start date: 01Apr2013. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Jun2022, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of vaccination failure, covid-19. The patient received Paxlovid to treat vaccination failure, covid-19, treatment start date: 28Jun2022, treatment stop date: 02Jul2022. No follow-up attempts are possible. No further information is expected.